Therapeutic Response

BRCA2 pathogenic variants status confers therapeutic sensitivity to Rucaparib in patients with Prostate Adenocarcinoma.

Statements

Source and description

Rubraca (rucaparib) [package insert]. FDA. The U.S. Food and Drug Administration granted accelerated approval to rucaparib for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy. The product label states to select patients for therapy based on an FDA-approved companion diagnostic for rucaparib.